Insulet Corp (STU:GOV)
€ 228.1 5 (2.24%) Market Cap: 17.41 Bil Enterprise Value: 17.87 Bil PE Ratio: 45.89 PB Ratio: 16.81 GF Score: 93/100

Insulet Corp to Discuss Omnipod® 5 Pivotal Data - Conference Call Transcript

Mar 20, 2021 / 04:30PM GMT
Deborah R. Gordon
Insulet Corporation - VP of IR

Good afternoon, everyone.

I'm Deb Gordon, Vice President of Investor Relations.

And thank you for joining us today for Insulet's investor webcast to discuss our Omnipod 5 pivotal trial results that were just presented a little while ago at ENDO 2021.

A PDF of the data that we're presenting today as well as a replay of this event will be available on our investor relations website.

Today's event will last about an hour, starting with prepared remarks, followed by a Q&A session. Dr. Trang Ly, our Senior Vice President and Medical Director, will present the Omnipod 5 pivotal data, followed by a discussion with Dr. Bruce Bode. And we're very excited to have Dr. Bode join us today. Not only is he principal investigator for our Omnipod 5 pivotal trial. He's principal investigator for our type 2 study, and he's also been involved in the research for all of the systems. Dr. Bode is a diabetes specialist with Atlanta Diabetes association and clinical associate professor in the Department of Medicine at Emory University.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot